Susceptibility of pentylenetetrazole-induced seizures in mice with Cereblon gene knockout.
Journal
BMB reports
ISSN: 1976-670X
Titre abrégé: BMB Rep
Pays: Korea (South)
ID NLM: 101465334
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
04
06
2020
pubmed:
28
8
2020
medline:
3
7
2021
entrez:
27
8
2020
Statut:
ppublish
Résumé
Epilepsy is a neurological disorder characterized by unpredictable seizures, which are bursts of electrical activity that temporarily affect the brain. Cereblon (CRBN), a DCAFs (DDB1 and CUL4-associated factors), is a well-established protein associated with human mental retardation. Being a substrate receptor of the cullin-RING E3 ubiquitin ligase (CRL) 4 complex, CRBN mediates ubiquitination of several substrates and conducts multiple biological processes. In the central nervous system, the largeconductance Ca2+-activated K+ (BKCa) channel, which is the substrate of CRBN, is an important regulator of epilepsy. Despite the functional role and importance of CRBN in the brain, direct injection of pentylenetetrazole (PTZ) to induce seizures in CRBN knock-out mice has not been challenged. In this study, we investigated the effect of PTZ in CRBN knock-out mice. Here, we demonstrate that, compared with WT mice, CRBN knock-out mice do not show the intensification of seizures by PTZ induction. Moreover, electroencephalography recordings were also performed in the brains of both WT and CRBN knockout mice to identify the absence of significant differences in the pattern of seizure activities. Consistently, immunoblot analysis for validating the protein level of the CRL4 complex containing CRBN (CRL4Crbn) in the mouse brain was carried out. Taken together, we found that the deficiency of CRBN does not affect PTZ-induced seizure. [BMB Reports 2020; 53(9): 484-489].
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Crbn protein, mouse
0
Pentylenetetrazole
WM5Z385K7T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
484-489Références
PLoS Comput Biol. 2015 Jan 08;11(1):e1004023
pubmed: 25569776
Genes Dev. 2014 May 1;28(9):929-42
pubmed: 24788516
Genome Biol. 2009;10(11):R130
pubmed: 19919682
Mol Cell. 2007 Jun 22;26(6):775-80
pubmed: 17588513
Leukemia. 2012 Nov;26(11):2326-35
pubmed: 22552008
CNS Neurol Disord Drug Targets. 2018;17(4):272-279
pubmed: 29437015
Nature. 2006 Oct 5;443(7111):590-3
pubmed: 16964240
FEBS Lett. 2009 Feb 18;583(4):633-7
pubmed: 19166841
Epilepsy Res. 2012 Dec;102(3):180-7
pubmed: 22742962
Front Psychiatry. 2012 Mar 19;3:19
pubmed: 22457654
Nature. 2014 Aug 7;512(7512):49-53
pubmed: 25043012
Biochim Biophys Acta. 2011 Mar;1813(3):448-55
pubmed: 21232561
Neurology. 2004 Nov 23;63(10):1927-31
pubmed: 15557513
Cancer Lett. 2019 Dec 28;467:29-39
pubmed: 31574293
Diabetes. 2013 Jun;62(6):1855-64
pubmed: 23349485
Neurochem Int. 2000 Apr;36(4-5):471-82
pubmed: 10733015
J Neurosci. 2018 Apr 4;38(14):3571-3583
pubmed: 29530986
J Immunol Res. 2017;2017:9130608
pubmed: 28894755
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):105-13
pubmed: 14687864
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8771-6
pubmed: 27439875
Mol Cell. 2016 Mar 17;61(6):809-20
pubmed: 26990986
Nat Commun. 2014 May 21;5:3924
pubmed: 24845235
J Neurochem. 2005 Sep;94(5):1212-24
pubmed: 16045448
Biochem J. 2015 May 1;467(3):365-86
pubmed: 25886174
Nat Commun. 2018 Mar 12;9(1):1040
pubmed: 29531219
J Gen Physiol. 2016 Apr;147(4):291-308
pubmed: 27022190
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Neurosci. 1999 Aug 15;19(16):6733-9
pubmed: 10436030
Science. 2010 Mar 12;327(5971):1345-50
pubmed: 20223979